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Pain during and after coronavirus disease 2019:
Chinese perspectives
Feng Jianga,*, Wan-Li Yanga, Jia-Wei Wangb, Zhen Zhub, Ceng Luoc, Lars Arendt-Nielsend, Xue-Jun Songe
Abstract
The coronavirus disease 2019 (COVID-19) global pandemic poses a major threat to human health and health care systems.
Urgent prevention and control measures have obstructed patients’ access to pain treatment, and many patients with pain
have been unable to receive adequate and timely medical services. Many patients with COVID-19 report painful symptoms
including headache, muscle pain, and chest pain during the initial phase of the disease. Persistent pain sequela in patients
with COVID-19 has a physical or mental impact and may also affect the immune, endocrine, and other systems. However, the
management and treatment of neurological symptoms such as pain are often neglected for patients hospitalized with COVID-
19. Based on the China’s early experience in the management of COVID-19 symptoms, the possible negative effects of pre-
existing chronic pain in patients with COVID-19 and the challenges of COVID-19 prevention and control bring to the diagnosis
and treatment of chronic pain are discussed. This review calls to attention the need to optimize pain management during and
after COVID-19.
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1. Introduction
The coronavirus disease 2019 (COVID-19) pandemic has
dramatically changed the way people live around the world. In
particular, it has had a profound impact on normal medical
activities and required repositioning health care personnel to front
line services. To cope with the risk of hospital-acquired infection,
medical institutions have had to multiply health care costs and
resource use.5 However, patients with pain may not get better
care despite the increased health care spending. Importantly, to
reallocate resources to the emergency department, many non-
emergency departments at medical institutions have been
completely or partly closed, including many pain management
departments.16 This review, based on the Chinese experience,
attempts to uncover the increased risk of pain that patients with
COVID-19 may face and outline that pain may not only be a
symptom of COVID-19 but also one of the risk factors that
influence the improvement of COVID-19 and other patients. This
review will highlight and discuss China’s early experience in the
management of COVID-19 symptoms, including pain, and apply
this in a global context.
1.1. COVID-19 infection increases the risk of pain
Although pulmonary infection is the major symptom of SARS-
CoV-2 infection, more than a third of the patients with COVID-19
had different neurological symptoms which may involve the
central nervous system (dizziness, headache, impaired con-
sciousness, ataxia, and epilepsy) and the peripheral nervous
system (sensory system impairments and neuralgia) and skeletal
muscle damage/pain or chest pain.41 In some patients,
neurological symptoms may be the first or only manifestation of
COVID-19.2 In addition, patients with more severe SARS-CoV-2
infection are more likely to show neurological symptoms.41
Although severe pain is rare, different forms of pain are important
clinical manifestations. In a large study based on 1,099 patients
(926 nonsevere and 173 severe) collected in 552 Chinese
hospitals, 150 (13.6%) had headache and 164 (14.9%) had
muscle or/and joint 30 pain and 153 (13.9%) with sore throat.24
Because of the differences in study objectives, a very wide range
of pain prevalence was reported.
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1.2. Headache
Headache is one of themost frequent forms of pain during SARS-
CoV-2 infection. The exact incidence of headaches caused by
the virus needs further study, while most studies suggest
headache prevalence ranged between 6% and 21%.15,58
Whether the headache is caused by the virus invading the
nervous system directly or indirectly remains uncertain. An
autopsy report showed damage to the central nervous system
(CNS) as evidenced by brain edema and partial neuronal
degeneration.63 The presence of SARS-CoV-2 in the cerebro-
spinal fluid was confirmed by genome sequencing, indicating that
the virus may penetrate and cause damage to the CNS.4 Existing
knowledge about coronaviruses suggests that the coronavirus
family has a certain tropism for the CNS.8 Neuronal pathways
allow the virus to enter the CNS.1 The virus can infect sensory and
motor nerve endings to migrate, then achieve retrograde or
anterograde transport by movement protein, dynein protein, and
dynamic neurons to invade nerve tissues and cause infection of
immunocompetent microglia, astrocytes, and macrophages in
the CNS.3,56,57
1.3. Muscle pain
Muscle pain is another common symptom in patients with
COVID-19. When comparing the existing studies, the incidence
of muscle pain ranged between 7% and 32%.24,36,66 Since the
target receptor of SARS-CoV-2, ACE2, is present in almost all
tissues, including muscle tissues, the virus can attack skeletal
muscle cells directly, causing skeletal muscle weakness, fatigue,
pain, and injury.20,27,43,53 Rhabdomyolysis has been found in
patients with severe SARS-CoV-2 infection.13,19,29,58 Apart from
the direct cause, the inflammatory response induced by SARS-
CoV-2 infection may be another important cause of muscle
pain.59 Muscle injury caused by COVID-19 is characterized by a
significant increase in the levels of creatine kinase and lactate
dehydrogenase, and its pathophysiology is primarily believed to
be caused by excessive inflammation.33
1.4. Chest pain
Chest pain, while relatively rare, generally occurred in patients
with more severe symptoms especially when lesions are close to
the pleura with abundant nerves.7 A descriptive study of the
epidemiology and clinical characteristics of 99 cases of new
coronavirus pneumonia in Wuhan in 2019 showed that when
admitted to the hospital, most patients had fever or cough, and
some patients had chest pain (2%).11 Comparedwith the patients
with mild symptoms, the incidence of chest pain and dyspnea is
higher in critical patients. In the severe patients, chest pain may
be caused by the inflammatory reaction of the pleura. Their
alveolar tissue is severely damaged, resulting in dyspnea.
1.5. Other kinds of pain
Other types of pain are also found during the process of clinical
diagnosis. Researchers from Anglia Ruskin University found that
among 83 interviewees, there was a significant increase in eye
pain in the confirmed patients; 16% reported eye pain as one of
their symptoms.34 Sore throat was reported in 5% to 17.4% of
patients with COVID-19 in China.11,21,60 Of 76 patients with acute
abdominal pain, 9 patients (11.8%) were eventually diagnosed
with COVID-19.54
1.6. Pain sequela after COVID-19 in patients with or without
chronic pain
Those patients with COVID-19 who experience intense pain and
distress during their stay in the intensive care unit (ICU) seem to be
at a higher risk of developing chronic pain after discharge.32,39
Unfortunately, in the ICU, pain is often overlooked as being low
priority and thus poorly managed, even in a well-staffed and
skilled environment.50 It is important to consider how to
implement effective pain management in the ICU to reduce
acute pain and reduce the risk of chronic pain in patients with
COVID-19.31,50 Clinical practice guidelines for the prevention and
management of pain, agitation/sedation, delirium, immobility,
and sleep disruption in adult patients in the ICU have been
developed and adopted in many ICUs.14 This strategy can
obviously strengthen pain management of patients through
multidisciplinary management of symptoms, mobility, and
communication. Although there is not yet substantial evidence
to support the statement that pre-existing chronic pain may
worsen the pain during and after COVID-19, many severe chronic
diseases such as coronary artery disease, diabetes, cancer, and
chronic obstructive pulmonary disease are often accompanied by
pain and also heighten the risk of death during COVID-19.
Patients with chronic pain already experiencing depression,
inattention, fatigue, and insomnia may find COVID-19 symptoms
especially disturbing.
1.7. Presence of painmay affect the recovery fromCOVID-19
To concentrate available resources during the initial wave of
COVID-19, most medical institutions had to close nonintensive
care services including pain management departments.55
Besides the increased burden on the medical staff, patients with
severe chronic pain, the disabled, and the elderly had reduced
access to psychological and interdisciplinary treatments.30 A lack
of face-to-face counseling services complicates individual
assessment of analgesic use risk. When pain cannot be
effectively assessed and treated, quality of life is reduced and
treatment of underlying diseases may be impaired.47,64 The
presence of chronic pain can activate the
hypothalamus–pituitary–adrenal axis and alter the function of
the immune and endocrine systems.26,28,46,49,68 At the Renmin
Hospital of Wuhan University, a total of 663 patients with COVID-
19 admitted between January 2020 and February 2020 were
enrolled in a retrospective cohort study. Muscle pain was
significantly associated with severe COVID-19 (P 5 0.028) and
to the patients’ hospital course (P , 0.001). Muscle pain,
expectoration, and decreased albumin were believed to be
independent risk factors influencing patients’ improvement
during follow-up.66 Furthermore, groups such as the poor, the
widowed elderly, and the homeless are more likely to suffer from
chronic pain and comorbidities,42 have less access to health
care, and are a high-risk group for severe COVID-19.6
Online pain management programs where patients are in
contact with health care providers remotely are promising.62
Online resources can disseminate pain education and can
develop online training programs on pain self-management for
health care professionals, patients with pain, and relevant
personnel. Althoughmuch of the existing research is optimistic
about eHealth Care, studies may not adequately assess
groups without access or ability to use these services,
including children, the elderly, or those with intellectual
disabilities.16
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1.8. China’s approaches to pain control during and
after COVID-19
China’s response to COVID-19 has been rigorous. After the
outbreak, the Central Government’s Leading Group for Epidemic
Work swiftly formulated a response plan which put people’s lives
as the top priority. With the precise decision of the Chinese
government and the joint efforts of volunteers from all over the
country, the further expansion of the epidemic was finally
controlled, which laid a solid foundation for the Chinese control
of the epidemic throughout the country. Many of China’s
practices are worthy of discussion and reference.
1.9. Popularization of COVID-19 knowledge
Popularizing science and improving citizens’ scientific quality are
long-term concern of the Chinese government. This ensures that
the public can properly understand and scientifically protect
against the COVID-19 epidemic. In the very early days of the
epidemic, China published the basic knowledge of novel
coronavirus, the key points of self-protection, and the relevant
national epidemic prevention and control policies to the public on
the official government media, such as the Xinhua News Agency
and China Central Television. At the same time, authoritative
medical organizations, such as the Chinese Medical Association,
China Preventive Medicine Association, and Chinese Association
for the Study of Pain, educated the public through their official
information release platforms. Through their professional guid-
ance, self-health management of patients during the epidemic
period was strengthened. For example, the Chinese Association
for Science and Technology issued an article on home care and
rehabilitation guidance for patients with shoulder joint pain during
the epidemic.13 It is worth noting that newmedia platforms, which
are more easily accepted by the people, have played a huge role
in the prevention and control of the epidemic. Only when most
people are familiar with the correct knowledge and prevention
measures of COVID-19 can epidemic prevention work be
performed more effectively.
1.10. Setting up professional diagnosis and
treatment department
After the SARS epidemic and experience in 2003, China set up
professional fever clinics in general hospitals grade II and above
(grade III is the highest grade). All patients with fever, cough, and
pain were to be admitted to the fever clinic for diagnosis and
treatment. During the period of regular epidemic prevention and
control, the registration, imaging examination, nucleic acid
testing, isolation, reporting, treatment, and referral of patients
with fever and pain can be conducted in this department. The
fever clinics performed strict terminal disinfection operations. On
December 3, 2020, the State Council’s Joint Prevention and
Control Mechanism Press Conference announced that more
than 7,000 fever clinics had been completed nationwide.45
1.11. Standardize the use of analgesic and febrifuge drugs
Fever and pain are important early diagnostic indications for most
patients with COVID-19. The China National Drug Administration
issued an administrative order to further regulate the use of
analgesic and antipyretic drugs, even those not typically thought
of as drugs of abuse.17 Meanwhile, the National Health
Committee issued the “Expert Consensus on the Management
and Guidance of the Rational Use of Home Medications for
Common People During the Epidemic Period”18 and provided
pain management and pain medication training to all medical
staffs. The purpose of these measures is to guide both medical
staffs and patients on the correct use of medicines and correct
reporting of early symptoms.
1.12. Early detection of close contacts
Finding close contacts of confirmed patients can help detect
potentially infected persons by identifying trajectories and early
symptoms, clearly describe the entire transmission chain and
transmission network, and make epidemic control more effec-
tive.25 In January 2021, a few local caseswere reported in Beijing,
Shanghai, Hebei, and other places of China. The local
governments immediately organized large-scale epidemiological
follow-up. Most subsequent confirmed cases were close
contacts identified by epidemiological means. The scattered
outbreaks were controlled in only 1 month. Fever, pain, and other
symptoms of patients with COVID-19 after infection clearing and
discharge should also be included in the epidemiological
follow-up.
1.13. Improve the public treatment system of COVID-19
In developing countries, even in many developed countries, the
cost of treatment is a heavy burden for most patients with COVID-
19. This may lead some patients to report their symptoms
untruthfully. The Chinese government has designated special
medical hospitals in each city to treat patients with COVID-19. In
these institutions, free treatment including pain management for
people infected with COVID-19 is provided. All the treatment
costs are covered by the national public health insurance fund.
This measure has helped implement the “early detection, early
isolation, early treatment” guideline and fully guarantees the right
of every citizen to have fair access to medical services. According
to statistics from the China Medical Insurance Administration, in
the first quarter of 2020 alone, China’s public medical insurance
invested more than 19.3 billion yuan (approx. 3.1 billion US
dollars) for the treatment of patients with COVID-19.52 In addition,
to encourage the public to receive the COVID-19 vaccine and
ensure that low-income groups can also get the vaccine fairly,
China has announced free vaccination for all citizens, the cost of
which will be covered by the national public medical insurance
fund.
China has adopted multiple channels to ensure the pain
control needs of patients without COVID-19 are addressed. The
National Ministry of Civil Affairs continues to purchase social
medical services for poor people and actively encourages
relevant companies to provide pain management services. For
example, the Nationwide Hospice Service Program supported by
Li Ka-shing Foundation provided free pain management and
other services to approximately 15,000 patients with cancer pain
during the COVID-19 epidemic.12,35
1.14. Adjust the measures of pain management
As COVID-19 has changed the original medical treatment model,
pain management measures have been adjusted to minimize the
impact of COVID-19 on patients with pain and the probability
infection spread by patients with pain receiving unsupervised
medical treatment. Based on the experience of effective pre-
vention and treatment of SARS andMERS, 8 updated versions of
Diagnosis and Treatment Protocol for Novel Coronavirus
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Pneumonia have been issued by the National Health Commission
of China.44
The experts in the Department of Pain Medicine in Wuhan and
Shenzhen have implemented a series of measures to take better
care of the most vulnerable patients.55 After classification of
diagnosis and treatment planning, outpatients withmoderate and
below pain received prescription drugs and received tele-
medicine support at home. Outpatients with severe pain were
sent to clinic for rapid treatment. Any outpatients with confirmed
or suspected COVID-19 infection will be sent to the quarantine
area for further observation and treatment. For in-patients with
severe pain, the necessary pain treatment was ensured as much
as possible on the basis of minimizing contact.
Telemedicine is a convenient and safe way of providing pain
management service during and after COVID-19, including
instructions for taking medicine, relief of psychological symp-
toms, and at-home exercises.55 According to reports, the
medical staff in Wuhan mobile cabin hospitals organized patients
to conduct collective social activities, lead patients to practice
square dances and increased theatrical performances.61
After discharge from hospital, patients should be followed up
to see if sequelae are present.67 Recently, a book cowritten by
Chinese doctors and scientific researchers in the field of COVID-
19 prevention and treatment namedCOVID-19: The Essentials of
Prevention and Treatment was released worldwide. This book
recorded China’s experience in prevention, control, and treat-
ment for global reference.51
1.15. Promote traditional Chinese medicine treatment
Another highlight of COVID-19 treatment in China is the use of
traditional Chinesemedicine (TCM). Traditional Chinesemedicine
plays an important role in the treatment of patients with COVID-19
in China. China’s Diagnosis and Treatment Protocol for Novel
Coronavirus Pneumonia has included guidance on using TCM to
treat patients with COVID-19 at all stages. The essence of
Chinese medicine is applying medicine according to symptom-
based diagnosis.9 The main symptoms of the patients with
COVID-19 are fever, fatigue, pain, cough, myalgia/arthralgia,
gastrointestinal symptoms, and “thick fur on tongue” which can
be classified into dampness subtype on the basis of TCM
theory.10,11,65 In TCM, the core pathogenesis of COVID-19 is the
discomfort of the lungs and spleen caused by damp cold
distemper. Early corresponding treatment should aim at elim-
inating moisture, thereby releasing lungs and eliminating patho-
genic factors, so as to shorten the duration of fever, relieve
symptoms including pain, and reducemortality.40 There aremany
prescriptions and proprietary Chinese medicines which have
been used in relieving COVID-19 symptoms in China. Most
Chinese medicine guidelines define COVID-19 as an endemic,
toxic, humid, or warm infectious disease.48 Licorice is the most
frequently used Chinese medicine. Ephedra, bitter almond,
astragalus, scutellaria, patchouli, and honeysuckle are also
medicines that are frequently used. In Guangdong, a case study
of Tou-jie-qu-wen granules was conducted and promoted to 30
designated hospitals as the standard treatment for patients with
COVID-19.22 Pharmacological analysis showed that most of the
active components of these herbs have antiviral, immunomod-
ulatory, anti-inflammatory, and analgesic effects.23 In the process
of treating patients with COVID-19, the use rate of traditional
Chinese medicine in patients accounted for 90.6%, and the total
effective rate was reported as over 90%.52
In addition, physicians use traditional nondrug methods such
as acupuncture and massage as adjuvant therapy for patients.67
According to reports, stimulating the acupoint such as Tianzhu
(BL10), BL12, and GV14 can eliminate nasal discharge, pain of
the shoulders, and the back, while Neiguan (PC6) and Lieque
(LU7), or Juque (CV14), Qımén (LR14), and Zhaohai (KI6) can
relieve chest pain or/and shortness of breath.37 The traditional
exercises named Taiji and Ba-Duan-Jin et al. are also used in
rehabilitation training.38 The combination of TCM and modern
medicine is used to treat patients with COVID-19 in China, giving
full play to the respective possible strengths of TCM and modern
medicine therapy.
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